Asano M, Mori T, Takahashi K, Yasuno M
Division of Surgery, Tokyo Metropolitan Komagome Hospital.
Gan To Kagaku Ryoho. 1997 Jan;24(1):55-60.
Combined chemotherapy with 5-FU or UFT and CDDP was performed in 22 cases with inoperable advanced or recurrent colorectal cancer. When in hospital, 5-FU 375 mg/m2/day c.i.v.. (days 1-7) and CDDP 3.75 or 7.5 mg/m2/day i.v.. (days 1-5) were administered for as many weeks as possible, while for outpatients UFT 450 mg/m2/day po (days 1-7) and CDDP 3.75 or 7.5 mg/m2/day div. (days 2 and 5 were given for as many weeks as possible. The performance status (PS) of the cases at the beginning of the chemotherapy was lower than 3 in 15 patients and over 3 in 7 patients. The response rate in cases with no history of systemic 5-FU chemotherapy was 30%, and the mean NC period in all cases of NC was 170 days. Half of the symptoms were improved in cases with some symptoms before chemotherapy, and half of the patients whose PS was over 3 could leave the hospital after chemotherapy. Toxicity was seen in 80% of the cases, but those over grade 3 were seen in only 2 cases. The mean administration period of the chemotherapy was 180 days, which shows a high compliance of the method.
对22例无法手术的晚期或复发性结直肠癌患者进行了5-氟尿嘧啶（5-FU）或优福定（UFT）与顺铂（CDDP）的联合化疗。住院期间，持续静脉滴注5-FU 375 mg/m²/天（第1 - 7天）和顺铂3.75或7.5 mg/m²/天静脉注射（第1 - 5天），尽可能持续进行数周；门诊患者口服优福定450 mg/m²/天（第1 - 7天）和顺铂3.75或7.5 mg/m²/天分服（第2天和第5天），尽可能持续进行数周。化疗开始时，15例患者的体能状态（PS）低于3，7例患者的PS高于3。既往无全身5-FU化疗史的患者缓解率为30%，所有病情稳定（NC）病例的平均NC期为170天。化疗前有某些症状的患者中，一半的症状得到改善，PS高于3的患者中有一半在化疗后可以出院。80%的病例出现毒性反应，但3级以上毒性反应仅见于2例。化疗的平均给药期为180天，表明该方法的依从性较高。
